A Service For Professionals Sunday, October 22, 2017
Contact (202) 540-8337
Patents and Trademarks Today
A Service For Professionals Sunday, October 22, 2017 11614 Sources 411,181,282 Articles 3,134,516 Readers
Contact (202) 540-8337

OCTOBER 17 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm

/EIN News/ -- IRVINE, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Depomed, Inc. (“Depomed” or the “Company”) (Nasdaq:DEPO). Investors who purchased or otherwise acquired Depomed shares from February 26, 2015 through August 7, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm by October 17, 2017, the lead plaintiff motion deadline.

If you purchased Depomed shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

The Complaint alleges that during the Class Period, Depomed made false and/or misleading statements, and/or failed to disclose: that the Company engaged in questionable practices in connection with the sales and marketing of its opioid products; that this conduct would likely subject Depomed to heightened legal and regulatory scrutiny; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 7, 2017, Depomed revealed that it “recently received a request for information from the ranking minority member of the United States Senate Committee on Homeland Security and Governmental Affairs related to the promotion of opioids” and that Depomed had also received “subpoenas related to opioid sales and marketing from the Office of the Attorney General of Maryland and the United States Department of Justice.” When this news reached the public, Depomed’s stock price dropped materially, which caused investors harm according to the lawsuit.

If you want to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may be considered Attorney Advertising in certain jurisdictions.

Contact

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

Primary Logo

Powered by EIN News
Distribution channels: Consumer Goods, Law
Submit your press release